Haoyuan Pharmaceutical H1 Revenue Up 25.71% to RMB 1.648 Billion, Net Profit Rises 12.81%
Haoyuan Pharmaceutical disclosed its 2026 semi-annual report on August 26. During the reporting period, the company achieved operating revenue of RMB 1.648 billion, up 25.71% year-on-year; net profit attributable to shareholders of the listed company was RMB 171 million, up 12.81% year-on-year; and basic earnings per share stood at RMB 0.81. The company also announced a profit distribution plan, proposing a cash dividend of RMB 0.9 (pre-tax) per 10 shares.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceutical R&D Services, with intensity 30/100 and 60% confidence over a short term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.